Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

CzechiaBack to Czechia

Clinical trials in Olomouc – page 25

342 clinical trials in Olomouc, Czechia across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

CzechiaOur site in CzechiaKlinickeTesty.cz(opens in a new tab)
Olomouc at a glance
342
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

342 trials in Olomouc

Open in trial search

Dermatitis atopic

Not recruiting

Study on the Effectiveness and Safety of Amlitelimab for Patients Aged 12 and Older with Moderate-to-Severe Atopic Dermatitis Using Topical Corticosteroids

Registered drug
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Alopecia areata

Not recruiting

Long-Term Study of Ritlecitinib Tosilate for Adults and Adolescents with Alopecia Areata

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Pfizer Inc.

Transitional cell carcinoma

Not recruiting

Study of Disitamab Vedotin and Pembrolizumab for Patients with Untreated Advanced Urothelial Cancer Expressing HER2

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Seagen Inc.

Escherichia urinary tract infection

Not recruiting

Study of ExPEC9V vaccine for preventing invasive E.

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:ECOO15
  • Sponsor:Janssen Vaccines & Prevention B.V.

Colorectal cancer metastatic+4

Not recruiting

Study on PF-07220060, Letrozole, and Fulvestrant for Patients with Advanced Breast Cancer, Prostate Cancer, and Other Solid Tumors

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Pfizer Inc.

Clear cell papillary renal cell carcinoma

Not recruiting

Study Comparing Savolitinib and Durvalumab with Sunitinib and Durvalumab for Patients with Advanced Papillary Renal Cell Carcinoma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Gastroenteropancreatic neuroendocrine tumour disease

Not recruiting

Study comparing 177Lu-edotreotide versus everolimus in patients with inoperable progressive neuroendocrine tumors of gastroenteric or pancreatic origin

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:ITM Solucin GmbH

Study of Durvalumab and Tremelimumab for Patients with Limited Stage Small-Cell Lung Cancer After Chemoradiation Therapy

Not recruiting
Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Dextrose Bp
  • Sponsor:AstraZeneca AB

Bladder cancer

Not recruiting

Study on the Effectiveness of Durvalumab, Tremelimumab, and Chemotherapy in Patients with Advanced Bladder or Urinary System Cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Plasma cell myeloma

Not recruiting

Study Comparing Daratumumab with Drug Combination for Young Patients with Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplantation

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years
  • Substances:Bortezomib
  • Sponsor:Ceska Myelomova Skupina z.s.

Non-small cell lung cancer

Not recruiting

Study of Pembrolizumab for Patients with Early Stage Non-Small Cell Lung Cancer After Surgery and Standard Therapy

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer+1

Not recruiting

Study on Osimertinib and Chemotherapy for Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Other cities in Czechia

The busiest research cities in the country

All 159 cities in Czechia

Clinical research in Olomouc

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on multiple cancer types, including metastatic prostate cancer, lung cancer, and colorectal cancer. Research emphasizes innovative treatment approaches and combination therapies.

  • Prostate Cancer Treatment Evaluation
  • Lung Cancer Therapy Development
  • Cervical Cancer Treatment Comparisons

These trials aim to improve survival rates and treatment effectiveness across various cancer types.

02 Cardiovascular and Metabolic Disorders

Studies investigating treatments for heart failure prevention, obesity management, and cardiovascular disease. Focus on innovative therapeutic approaches and combination treatments.

  • Heart Failure Prevention Studies
  • Obesity Treatment Research
  • Cardiovascular Risk Management

Research aims to reduce cardiovascular events and improve patient outcomes.

03 Immunology and Inflammatory Conditions

Clinical investigations targeting Crohn's disease, chronic rhinosinusitis, and other inflammatory conditions. Studies evaluate novel therapeutic approaches and treatment optimization.

  • Inflammatory Bowel Disease Therapy
  • Autoimmune Disease Treatment
  • Infection Management Studies

Research focuses on improving treatment responses and patient quality of life.

Back to CzechiaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.